
    
      The primary objective is to assess the safety of deferasirox in treating non-transfusion iron
      overload in patients with PCT.

      The secondary objective is to assess the effectiveness of deferasirox treatment :

      After 3 and 6 months to:

      •Lower serum ferritin from abnormal to normal standard ranges specified for males and females
      in this patient population.

      After 6 months to :

      •Lower liver iron content after 24 weeks of treatment measured by liver MRI T2

      After 3 and 6 months to :

        -  Improve clinical symptoms, i.e. improvement in skin lesions (reduction or no new bullae
           formation), and skin fragility (photographs will be used).

        -  Reduce porphyrin levels.
    
  